Zacks Investment Research downgraded shares of EVOKE PHARMA (EVOK) from OUTPERFORM to NEUTRAL on January 15, 2015, with a target price of $8.30.
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on EVOKE PHARMA (EVOK),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment